Boji Medical Technology Co Ltd
Boji Medical Technology Co Ltd provides healthcare diagnostics services and related products, primarily generating revenue through diagnostic testing and research services.
Business. Boji Medical Technology Co Ltd (300404.SZ) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in China and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Boji Medical Technology Co Ltd (300404.SZ) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in China and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Boji Medical Technology Co Ltd maintains a conservative capital structure, with a debt-to-equity ratio of 0.05, indicating minimal leverage. The company's liquidity position is characterized as medium, with a current ratio of 1.96, suggesting it can cover short-term obligations but with limited excess cash. Free cash flow for the period was 16.97 million CNY, while operating cash flow was 26.78 million CNY.
Profitability metrics show a return on equity of 2.96% and a return on assets of 1.98%, both below the industry median for Biotechnology & Medical Research firms. The company's gross margin is 30.19% (224.04 million CNY gross profit on 742.02 million CNY revenue), but operating margin is only 2.50% (18.51 million CNY operating income), indicating high operating expenses relative to revenue.
The company's geographic and segment exposure is not disclosed in the available data, but revenue concentration is not explicitly reported. Given the lack of segmental breakdown, it is unclear whether the company is overexposed to a single product line or geographic region.
Growth trajectory appears modest, with no forward-looking revenue guidance provided. Historical revenue of 742.02 million CNY suggests a stable but not accelerating business model. Analysts have assigned a mean recommendation of 2.00, indicating a "Hold" rating, with only one "Buy" recommendation and no "Strong Buy" or "Sell" ratings.
Risk factors include a negative net cash position after subtracting total debt, which could constrain operational flexibility. The company has a low dilution risk, with no difference between basic and diluted shares outstanding. No recent equity issuance or dilutive events are reported in the available data.
No recent filings or transcripts are available in the provided data to assess management commentary or strategic shifts. The company's capital expenditure of -29.35 million CNY suggests asset disposals or a reduction in capital spending.
- The company maintains a low debt-to-equity ratio of 0.05, indicating a conservative capital structure.
- Return on equity of 2.96% is below the industry median, suggesting suboptimal use of equity capital.
- Free cash flow of 16.97 million CNY provides some flexibility but is not sufficient for aggressive reinvestment.
- Analysts have assigned a "Hold" rating, with no strong buy or sell recommendations.
- The company's operating margin of 2.50% is low, indicating high operating costs relative to revenue.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,17 |
| Revenue | —no estimate | —no estimate | 999,0M CNY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Boji Medical Technology Co Ltd Market data — financials · 2026-05-26
- Boji Medical Technology Co Ltd Market data — analyst estimates · 2026-05-26